HPV Vaccination Strategy for 14-year-old Females and Economic Returns for Cervical Cancer Prevention in Wuxi City, China: a Cost Effectiveness Analysis

Overview

Journal Cost Eff Resour Alloc

Publisher Biomed Central

Date 2024 Sep 5

PMID 39237947

Authors

Jingfeng Jiang

Fanqi Zhao

Xiang Hong

Xuwen Wang

Affiliations

Soon will be listed here.

Abstract

Background: Since December 2021, Wuxi, China has offered a two-dose human papillomavirus (HPV) vaccination to 14-year-old females for free. This study evaluated the costs and benefits of this vaccination scheduled in the Expanded Program on Immunization in Wuxi from the perspective of the cities' demographic characteristics, economic development, and policy support.

Methods: The model-based economic evaluation used TreeAge Pro software to construct a decision tree-Markov model for the vaccination strategy in which 100,000 14-year-old females received two doses of bivalent HPV vaccine or no vaccination. Costs and effects of the strategy were assessed from a societal perspective through literature research and data obtained from the Wuxi Centre for Disease Control and Prevention. Univariate, multivariate, and probabilistic sensitivity analyses assessed the stability of the findings.

Results: The cost of the bivalent HPV vaccine in Wuxi is 711.3 CNY. The two-dose of bivalent HPV vaccine for 100,000 14-year-old females would cost an additional 658,016 CNY compared to no vaccination, but would result in 1,960 Quality Adjustment Years of Life (QALYs). Using the per capita gross domestic product of 187,415 CNY in 2021 in Wuxi as the willingness-to-pay threshold, the vaccination strategy costs 3,357.37 CNY per QALY gained, which is much lower than the threshold, suggesting that it is a very cost-effective strategy. In addition, the vaccine strategy reduced the incidence of cervical cancer by 300 cases and cervical cancer deaths by 181 cases, representing a benefit-cost ratio of 2.86 (> 1) when health output outcomes were measured in monetary terms. These results suggested that the vaccination strategy was advantageous. Sensitivity analyses showed that changes in the parameters did not affect the conclusions and that the findings were robust.

Conclusions: Compared to no vaccination, the delivery of two doses of bivalent HPV vaccine for 14-year-old females was a more highly cost-effective and optimal strategy.

References

Zhao F, Lewkowitz A, Hu S, Chen F, Li L, Zhang Q . Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012; 131(12):2929-38. PMC: 3435460. DOI: 10.1002/ijc.27571. View

Mo X, Tobe R, Wang L, Liu X, Wu B, Luo H . Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC Infect Dis. 2017; 17(1):502. PMC: 5516327. DOI: 10.1186/s12879-017-2592-5. View

Zheng X, Chen G, Huang S . [Updates on adenocarcinomas of the uterine corpus and the cervix in the 5th edition of WHO classification of the female genital tumors]. Zhonghua Bing Li Xue Za Zhi. 2021; 50(5):437-441. DOI: 10.3760/cma.j.cn112151-20201021-00797. View

Tao S, Peng J, Wang Y, Zhang G, Chen Z, Zhao F . [Study on direct economic burden and influencing factors in patients with cervical cancer and precancerous lesions]. Zhonghua Yu Fang Yi Xue Za Zhi. 2018; 52(12):1281-1286. DOI: 10.3760/cma.j.issn.0253-9624.2018.12.017. View

. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine. 2017; 35(43):5753-5755. DOI: 10.1016/j.vaccine.2017.05.069. View

Sabatini M, Chiocca S . Human papillomavirus as a driver of head and neck cancers. Br J Cancer. 2019; 122(3):306-314. PMC: 7000688. DOI: 10.1038/s41416-019-0602-7. View

Van de Velde N, Brisson M, Boily M . Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007; 165(7):762-75. DOI: 10.1093/aje/kwk059. View

Qiao Y, Wu T, Li R, Hu Y, Wei L, Li C . Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. J Natl Cancer Inst. 2019; 112(2):145-153. PMC: 7019098. DOI: 10.1093/jnci/djz074. View

Rosettie K, Joffe J, Sparks G, Aravkin A, Chen S, Compton K . Cost-effectiveness of HPV vaccination in 195 countries: A meta-regression analysis. PLoS One. 2021; 16(12):e0260808. PMC: 8687557. DOI: 10.1371/journal.pone.0260808. View

10.

Guo M, Xu J, Du J . Trends in cervical cancer mortality in China from 1989 to 2018: an age-period-cohort study and Joinpoint analysis. BMC Public Health. 2021; 21(1):1329. PMC: 8259057. DOI: 10.1186/s12889-021-11401-8. View

11.

Walker D, Hutubessy R, Beutels P . WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine. 2009; 28(11):2356-9. DOI: 10.1016/j.vaccine.2009.06.035. View

12.

Ye Z, Liu Z, Cui S, Chu Z, Jiang Y, Xu J . High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China. Front Med (Lausanne). 2021; 8:763564. PMC: 8639684. DOI: 10.3389/fmed.2021.763564. View

13.

Ma X, Yang M . The correlation between high-risk HPV infection and precancerous lesions and cervical cancer. Am J Transl Res. 2021; 13(9):10830-10836. PMC: 8507010. View

14.

Luo Y, He H, Tang X, Wang S, Zhang J, Wu T . Cost-effectiveness of 2-dose human papillomavirus vaccination for 12-year-old girls in Zhejiang Province: implications for China's expanded program on immunization. Hum Vaccin Immunother. 2020; 16(7):1623-1629. PMC: 7482859. DOI: 10.1080/21645515.2019.1711299. View

15.

Qiao Y . [Epidemiology of HPV infection and cervical cancer and perspective of HPV vaccination in Chinese women]. Zhonghua Liu Xing Bing Xue Za Zhi. 2008; 28(10):937-40. View

16.

Ostor A . Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993; 12(2):186-92. View

17.

Song X, Zhao Q, Zhou Z, Fang Y . [Health economic evaluation of bivalent human papilloma virus vaccine in China: based on the dynamic model]. Zhonghua Yu Fang Yi Xue Za Zhi. 2017; 51(9):814-820. DOI: 10.3760/cma.j.issn.0253-9624.2017.09.008. View

18.

Sinanovic E, Moodley J, Barone M, Mall S, Cleary S, Harries J . The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine. 2009; 27(44):6196-202. DOI: 10.1016/j.vaccine.2009.08.004. View

19.

Zhao Z, Pan X, Lv S, Xie Y, Zhang S, Qiao Y . Quality of life in women with cervical precursor lesions and cancer: a prospective, 6-month, hospital-based study in China. Chin J Cancer. 2014; 33(7):339-45. PMC: 4110466. DOI: 10.5732/cjc.013.10139. View

20.

Lee H, Hur S, Jang H, Lee I, Sohn W, Van Kriekinge G . Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea. Asian Pac J Cancer Prev. 2019; 20(2):425-435. PMC: 6897004. DOI: 10.31557/APJCP.2019.20.2.425. View